Patients | 1 | 2 | 3 | 4 | 5 |
---|---|---|---|---|---|
Gender | Female | Male | Female | Male | Female |
Age (years) | 52 | 31 | 45 | 71 | 75 |
Smoking history | Never | Never | Never | Ever | Never |
Lymphovascular invasion | Absent | Present | Absent | Absent | Absent |
Tumor differentiation | Moderate | Moderate | Moderate | Moderate | Moderate |
Stage | T1bN0M0 | T1cN1M0 | T1cN0M0 | T1bN0M0 | T1cN0M0 |
Pathological type | MPA | MPA | MPA | MPA | LA |
Mutation status | ROS1+; EML4-ALK+ | ROS1+; EML4-ALK+ | EGFR L858R+; ROS1+ | EGFR L858R+; ROS1+ | EGFR 19-del+; ROS1+ |
Therapeutic intervention | Surgery; chemotherapy; crizotinib | Surgery; chemotherapy; crizotinib | Surgery; chemotherapy; EGFR inhibitors | Surgery; chemotherapy; EGFR inhibitors | Surgery; chemotherapy; EGFR inhibitors |
Outcomes | Partial response | Partial response | Partial response | Recurrence | Partial response |